Unusual outcome of treatment of thymoma with immunotherapy: case report
This case highlights the potential efficacy of ICI in thymoma treatment, emphasizing the delicate balance required between immunosuppression and immunotherapy for optimal outcomes. Achieving this delicate balance is vital for optimizing patient outcomes while minimizing the risk of severe complications and ensuring that both the paraneoplastic syndrome and the tumor itself are adequately managed. This consideration is particularly important when developing future clinical trials for thymoma, where the complex interplay between these therapies must be carefully evaluated to design effective and safe treatment protocols.
Authors
- Konstantinos Leventakos (ORCID: https://orcid.org/0000-0001-9784-8603)
- Julian R. Molina (ORCID: https://orcid.org/0000-0002-9962-4635)
- Mohamed Shanshal (ORCID: https://orcid.org/0009-0005-0775-2680)
- Jenesse Nicole Moffett
- Joseph Maakaron (ORCID: https://orcid.org/0000-0002-1732-6694)
- Kaushal Parikh (ORCID: https://orcid.org/0000-0001-6759-9351)
- A. Luce
- Anna J. Schwecke
Institutions
- University of Minnesota (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Mediastinum
- Published
- 2024-12-01
- DOI
- https://doi.org/10.21037/med-24-20
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.37
Funders
- Amgen
- AstraZeneca
- Gilead Sciences
- Regeneron Pharmaceuticals
- Jazz Pharmaceuticals
- Atara Biotherapeutics
- Mirati Therapeutics
- Janssen Biotech